Analysts think SKYE stock price could increase by 310%
Jul 10, 2025, 11:25 AM
-16.78%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
7 analysts think SKYE stock price will increase by 309.93%. The current median analyst target is $17.34 compared to a current stock price of $4.23. The lowest analysts target is $14.14 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.